Cargando…
Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis
BACKGROUND: Dry eye disease (DED) is a disorder characterized by loss of tear film homeostasis that causes ocular surface inflammation and damage. The incidence of DED increases with age. Cyclosporine ophthalmic solution 0.09% (CEQUA(®); OTX-101), cyclosporine ophthalmic emulsion 0.05% (Restasis(®);...
Autores principales: | Karpecki, Paul, Barghout, Victoria, Schenkel, Brad, Huynh, Lynn, Khanal, Anamika, Mitchell, Brittany, Yenikomshian, Mihran, Zanardo, Enrico, Matossian, Cynthia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10621228/ https://www.ncbi.nlm.nih.gov/pubmed/37919692 http://dx.doi.org/10.1186/s12886-023-03174-y |
Ejemplares similares
-
Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye
por: White, Darrell E, et al.
Publicado: (2019) -
Safety and efficacy of lifitegrast 5% ophthalmic solution in contact lens discomfort
por: Gonzalez, Agustin L
Publicado: (2018) -
Preclinical Efficacy Comparison of Cyclosporine Ophthalmic Solution 0.09% vs Cyclosporine Ophthalmic Emulsion 0.05% vs Ciclosporin Ophthalmic Emulsion 0.1% in a NOD Mouse Model of Dry Eye Disease
por: Burade, Vinod, et al.
Publicado: (2020) -
Dry Eye Treatment with Topical Cyclosporine 0.1% in Chondroitin Sulfate Ophthalmic Emulsion
por: Matossian, Cynthia, et al.
Publicado: (2021) -
Safety and tolerability of lifitegrast ophthalmic solution 5.0%:
Pooled analysis of five randomized controlled trials in dry eye
disease
por: Nichols, Kelly K, et al.
Publicado: (2018)